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Abstract
Background: There is a lack of clinical data on the validity of neoadjuvant chemotherapy in the treatment
of ovarian cancer. The aim of this study was to compare the impact of the adjuvant and neoadjuvant
chemotherapy regimens on the clinical outcomes in patients with advanced ovarian cancer.
Methods: We performed a retrospective analysis of 574 patients with advanced ovarian cancer admitted
to four Lithuanian oncogynaecology departments during 1993–2000. The conventional combined
treatment of cytoreductive surgery and platinum-based chemotherapy was applied to both the group that
underwent neoadjuvant chemotherapy (n = 213) and to the control group (n = 361). The selection
criterion for neoadjuvant chemotherapy was large extent of the disease. Overall and progression-free
survival rates and survival medians were calculated using life tables and the Kaplan-Meier method.
Results: There was no difference in median overall survival between stage III patients treated with
adjuvant chemotherapy and neoadjuvant chemotherapy (25.9 months vs. 29.3 months, p = 0.2508) and
stage IV patients (15.4 months vs. 14.9 months, p = 0.6108). Similarly, there was no difference in median
progression-free survival between stage III patients treated with adjuvant chemotherapy and neoadjuvant
chemotherapy (15.7 months vs. 17.5 months, p = 0.1299) and stage IV patients (8.7 months vs. 8.2 months,
p = 0.1817). There was no difference in the rate of the optimal cytoreductive surgery between patients
who underwent the neoadjuvant chemotherapy and patients primarily treated with surgery (n = 134, 63%
vs. n = 242, 67%, respectively).
Conclusion: There was no difference in progression-free or overall survival and in the rate of optimal
cytoreductive surgery between the neoadjuvant and adjuvant chemotherapy groups despite the fact that
patients receiving neoadjuvant chemotherapy had a more extensive disease. Multivariate analysis failed to
prove that neoadjuvant chemotherapy could be considered as an independent prognostic factor for
survival, and the findings need to be investigated in the future prospective randomised studies.
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Background
Ovarian cancer is the leading cause of death among all
gynaecologic cancers in Europe and the United States. The
incidence of ovarian cancer has been steadily increasing
over the past 10 years in many countries, reaching the
overall lifetime risk of 1.8% [1]. Despite new medical and
surgical advances and new chemotherapeutic regimens,
the overall 5-year survival for patients with stage III and IV
epithelial ovarian cancer has remained relatively
unchanged over the last 40 years. After the application of
cytoreductive surgery and adjuvant chemotherapy with
cisplatin/cyclophosphamide, the 5-year survival among
stage III cases is 10–20%, and among stage IV cases – even
below 10%. The optimisation of the treatment is the only
way to prolong the survival of such patients.
Frei in 1982 originally introduced the definition of neoad-
juvant chemotherapy to describe chemotherapy treatment
of primary solid tumours before surgical ablation.
Tumour downstaging has been demonstrated for a variety
of tumour types after neoadjuvant chemotherapy. Unlike
most solid tumour types, resection of metastatic sites from
ovarian cancer is an accepted practice. It was assumed that
optimal cytoreductive surgery could be performed in only
about 50% of patients with ovarian cancer stages III or IV.
In this group of patients, neoadjuvant chemotherapy was
applied as an alternative to conventional surgery. Neoad-
juvant chemotherapy resulted in adequate tumour shrink-
age and allowed for the surgical treatment of tumours
previously considered to be unresectable. Neoadjuvant
chemotherapy could lead to optimal conditions for
cytoreductive surgery and further increase the survival
rate. There is a number of assumed advantages and poten-
tial disadvantages of neoadjuvant chemotherapy. The pro-
posed benefits include tumour downstaging, which
allows for more conservative surgery or more optimal
cytoreductive surgery for unresectable tumours. The
potential disadvantages include the selection of resistant
tumour cell clones, less complete tumour downstaging,
and higher local relapse as a result of more conservative
surgery and compromised wound healing. Retrospective
data support a survival benefit to maximum tumour
reduction in advanced stage ovarian cancer. Bristow RE et
al. in a meta-analysis of 6885 patients demonstrated a sig-
nificant positive correlation between the percentage of
maximal cytoreduction and a log median survival time
[2]. However, 50 to 60% of patients with advanced dis-
ease are not optimally debulked [3]. For this subset of
patients, the overall prognosis is worse despite significant
heterogeneity in tumour chemosensitivity.
Optimal surgery after neoadjuvant chemotherapy is feasi-
ble for 60–94% of patients with advanced ovarian cancer
[4-8]. The responses of ovarian cancer to neoadjuvant
chemotherapy vary from 60% to 80%. This allows for pre-
dicting chemosensitive tumours after neoadjuvant chem-
otherapy. Patients with tumours sensitive to
chemotherapy can be treated with optimal cytoreductive
surgery, and increased overall and progression-free sur-
vival can be expected. In contrast, the feasibility of opti-
mal surgery and the prognosis of patients with
chemoresistant tumours are lesser.
The results of studies on neoadjuvant chemotherapy are
presented in Table 1. In many studies, surgery was per-
formed after 3 to 4 chemotherapy cycles due to smaller
chemotherapy-induced fibrosis compared to fibrosis that
develops after six courses of chemotherapy. Earlier studies
showed that second-look surgery after 6 cycles of chemo-
therapy did not increase the survival of patients.
Recently, the efficiency of neoadjuvant chemotherapy in
ovarian cancer treatment has been widely discussed, but
data for the legitimation of this treatment technique are
not sufficient. We found that it is important to analyse
and share experience in clinical practice due to the favour-
able situation in Lithuania where there is already a formed
tradition to apply neoadjuvant chemotherapy.
The aim of this study was to evaluate the role of neoadju-
vant chemotherapy in the management of advanced ovar-
ian cancer compared to adjuvant chemotherapy, and to
determine the impact of the neoadjuvant chemotherapy
on the optimisation of cytoreductive surgery.
Methods
The study included 574 patients with advanced ovarian
cancer (FIGO stages III – IV) treated in four Lithuanian
oncogynaecology departments during 1993–2000. The
information about the patients for this study was
obtained from medical records. All the studied patients
underwent combined treatment of cytoreductive surgery
and chemotherapy CP scheme (Cisplatin  75 mg/m2  +
Cyclophosphamide 750 mg/m2 every 3 weeks). The patients
were treated with neoadjuvant chemotherapy (3 cycles of
chemotherapy, cytoreductive surgery, and 3–5 cycles of
chemotherapy) or adjuvant chemotherapy (cytoreductive
surgery and 6–8 cycles of chemotherapy). Clinical find-
ings and diagnostic imaging findings were used to decide
whether to start the treatment with surgery or with chem-
otherapy. The selection criterion for neoadjuvant chemo-
therapy was the large extent of the disease – large volume
of ascites, and large tumours in pelvis or abdomen
detected by palpation or radiologically. The optimal
cytoreduction in this analysis was considered to be
achieved when the largest tumour diameter of residual
disease was less than 2 cm. Patients treated with 6–8 cycles
of the first line chemotherapy were included into the
study. Prolongation of chemotherapy (8 cycles) was per-
formed to patients who responded to chemotherapy.BMC Cancer 2006, 6:153 http://www.biomedcentral.com/1471-2407/6/153
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Characteristics of patients, disease, and treatment are pre-
sented in Table 2.
The last date of follow-up was December 31st 2003. The
dates of death and the cause of death were obtained from
the records of the Lithuanian Cancer Registry. No patients
were found alive by December 31st 2003, and no other
causes of death rather than ovarian cancer were certified in
the death certificates. Two endpoints have been used in
the study – the date of death (overall survival) and the
date of disease progression (progression-free survival).
Overall and progression-free survival rates and survival
medians were calculated using life tables and the Kaplan-
Meier method. The univariate and multivariate Cox pro-
portional hazards modelling was applied in order to eval-
uate the significance of prognostic factors (age,
morphology, treatment (adjuvant or neoadjuvant chemo-
therapy), the optimality of surgery, and the duration of
first-line chemotherapy) on the overall survival and dis-
ease-free survival. The survival estimates and the Cox pro-
portional hazard modelling were performed using
procedures of the STATA (version 7). The hazard ratio was
calculated in order to establish the difference in the degree
of survival between the groups, and to account for differ-
ences that might have been the effects of tumour stage,
treatment, age, and other patient characteristics. The ratio
of less than one indicated fewer deaths compared to the
reference group, whereas the ratio greater than one indi-
cated the opposite. The log-rank test was used to investi-
gate the difference in overall and disease-free survival rates
between the studied groups. Mantel-Haenszel estimate
was used to estimate the odds ratio of cytoreductive sur-
gery followed by neoadjuvant treatment. Estimates were
also controlled by age and stage. All the statistical tests
were two-tailed, and p-values of less than 0.05 were con-
sidered to be significant. The study was approved by the
local ethical committee (approval number – BE-2-53-A).
Results
In the group of patients who underwent neoadjuvant
chemotherapy, the median overall survival was 712 days
(23.7 months), [95% CI 668–769], and the median pro-
gression-free survival – 400 days (13.3 months), [95% CI
347–465]. In the group of patients who received conven-
tional treatment (adjuvant chemotherapy), the median
overall survival was 762 days (25.4 months), [95% CI
730–783], and the median progression-free survival – 451
[95% CI 410–501] days (15 months). No statistically sig-
Table 1: Retrospective studies in which patients with advanced ovarian cancer were treated with neoadjuvant chemotherapy followed 
by cytoreductive surgery.
Authors No. of patients treated with 
neoadjuvant chemotherapy
Main conclusion
Kuhn W et al. (8) 37 Better median survival in the group treated with neoadjuvant chemotherapy 
compared with the group treated with primary cytoreductive surgery
Onnis A et al. (9) 88 In 46% of operated patients, the residual tumour was < 2 cm. An improvement in 
the quality of surgery and disease-free period was observed, while survival rate did 
not improve when comparing the neoadjuvant chemotherapy group to the group 
that received adjuvant chemotherapy
Shimizu Y et al. (10) 74 In 46% of operated patients, the residual tumour was < 2 cm. Survival for the 
optimally debulked neoadjuvant chemotherapy group was significantly higher than 
that for the optimally debulked adjuvant chemotherapy group
Vergote I et al. (11) 75 Crude survival was higher when selecting about one-half of patients for 
neoadjuvant chemotherapy
Surwit E. et al. (12) 29 Median survival was 22 months
Schwartz PE et al. (13) 59 No statistical difference was observed in overall and progression-free survival 
between the group treated with neoadjuvant chemotherapy and the 
conventionally treated group
Jacob JH et al. (14) 22 The same survival as in 18 matched controls
Lim JT et al. (15) 30 Neoadjuvant chemotherapy can make patients operable
Lawton FG et al. (16) 36 78% of patients were treated with neoadjuvant chemotherapy, of whom in 89% 
the residual tumour was < 2 cm
Ansquer Y et al. (17) 54 Better survival of patients treated with neoadjuvant chemotherapy compared to 
patients with non-debulked tumours
Recchia F et al. (18) 34 Median survival was 28 months for stage IV patients
Loizzi V et al. (19) 30 Survival in the neoadjuvant and adjuvant chemotherapy groups was similar
Kayikcioglu F et al. (20) 45 Primary neoadjuvant chemotherapy followed by cytoreductive surgery did not 
appear to worsen the prognosis
Morice P et al. (21) 57 Survival rates were similar in patients who underwent interval debulking surgery 
or primary debulking surgery
Ivanov S et al. (22) 46 The five-year survival rate following the neoadjuvant chemotherapy was the same 
as in case of conventional chemotherapyBMC Cancer 2006, 6:153 http://www.biomedcentral.com/1471-2407/6/153
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nificant difference was observed in the median overall sur-
vival between the group treated with neoadjuvant
chemotherapy and the conventionally treated group (p =
0.1310) (Figure 1). No statistical difference was found in
the median progression-free survival between neoadju-
vant and adjuvant chemotherapy groups (p = 0.078) (Fig-
ure 2).
The median overall survival in stage III patients treated
with neoadjuvant chemotherapy was 778 days (25.9
months) [95% CI 723–850], and in those treated conven-
tionally – 879 days (29.3 months) [95% CI 780–951] (p
= 0.2508). The median progression-free survival in stage
III patients treated with neoadjuvant chemotherapy was
471 days (15.7 months) [95% CI 388–515], and in those
treated with adjuvant chemotherapy – 524 days (17.5
months) [95% CI 478–567] (p = 0.1299). The median
survival in stage IV patients treated with neoadjuvant
chemotherapy was 463 days (15.4 months) [95% CI 403–
503], and in those treated conventionally – 446 days
(14.9 months) [95% CI 411–502] (p  = 0.6108). The
median progression-free survival in stage IV patients
treated with neoadjuvant chemotherapy was 261 days
(8.7 months) [95% CI 237–291], and in those treated
with adjuvant chemotherapy – 245 days (8.2 months)
[95% CI 213–287] (p = 0.1817).
There were no significant differences in overall survival
between both treatment groups in case of serous (p  =
0.396), endometrioid (p = 0.197), and mucinous tumours
(p = 0.256). No significant differences in progression-free
survival between neoadjuvant and standard treatment
groups were found in case of serous (p = 0.299), endome-
trioid (p = 0.098), and mucinous tumours (p = 0.509)
either.
No statistical difference was observed in the overall sur-
vival (p = 0.065) or in the progression-free survival (p =
0.094) between the group treated with neoadjuvant
chemotherapy and the conventionally treated group for
those patients who underwent optimal cytoreduction. No
statistical difference was observed in the overall survival (p
= 0.117) or in the progression-free survival (p = 0.791)
between the group treated with neoadjuvant chemother-
apy and the conventionally treated group for those
patients who underwent not optimal cytoreduction. The
analysis of subgroups of patients with different histologi-
cal subtypes of tumours showed no significant difference
in overall and progression-free survival for optimally and
suboptimally debulked patients between neoadjuvant
chemotherapy and standard treatment.
Table 2: Characteristics of patients, disease, and treatment
Feature Neoadjuvant chemotherapy Adjuvant chemotherapy Total
Number of patients 213 361 574
Stage:
III 165 305 470
IV 48 56 104
Age by years:
<65 123 236 359
>65 90 125 215
Morphology:
Serous 84 135 219
Mucinous 48 67 115
Endometrioid 49 118 167




Optimal 134 242 376
Suboptimal 79 119 198
Number of chemotherapy 
cycles
6 cycles 109 244 353
8 cycles 104 117 221BMC Cancer 2006, 6:153 http://www.biomedcentral.com/1471-2407/6/153
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After the neoadjuvant chemotherapy, optimal cytoreduc-
tive surgery was performed in 134 patients (63%). Opti-
mal cytoreductive surgery was also performed in 242
conventionally treated patients (67%). Similar rates of
optimal cytoreductive surgery were established in the neo-
adjuvant chemotherapy and conventional therapy groups
for stage III patients younger than 65 years of age (79% vs.
78%). The possibility to perform optimal cytoreduction
for stage III patients up to 65 years of age did not differ
when choosing either adjuvant or neoadjuvant treatment
(OR = 1.06 [0.58–2.00], p = 0.839). Similar rates of opti-
mal cytoreductive surgery were established in the neoad-
juvant chemotherapy and conventional therapy groups
for stage III patients older than 65 years of age (66% vs.
62%). Possibilities to perform optimal surgery for stage III
patients aged over 65 years in comparison with the
younger ones decreased – only two thirds of all patients
aged over 65 years were debulked optimally. The possibil-
ity of optimal surgery was a bit greater after neoadjuvant
chemotherapy, comparing to adjuvant chemotherapy, but
no statistically significant difference between these treat-
ment methods was found (OR = 1.18 [0.58–2.42], p =
0.626). Similar rates of optimal cytoreductive surgery
were established in the neoadjuvant chemotherapy and
conventional therapy groups for stage IV patients younger
than 65 years of age (36% vs. 54%). The possibility to
undergo optimal surgery did not significantly differ for
stage IV patients younger than 65 years of age irrespec-
tively of whether the treatment was started with surgery or
with adjuvant chemotherapy (OR = 0.48 [0.12–1.83], p =
0.226). Similar rates of optimal cytoreductive surgery
were established in the neoadjuvant chemotherapy and
conventional therapy groups for stage IV patients older
than 65 years of age (12% vs. 15%). The possibility of
optimal surgery for the patients aged over 65 years
remained the same in both groups irrespectively of
whether the treatment was started with surgery or with
neoadjuvant chemotherapy (OR = 0.77 [0.11–4.52], p =
0.741).
The possibility to perform optimal surgery after neoadju-
vant chemotherapy did not significantly increase for
patients with serous (OR = 0.37 [0.44–1.54], p = 0.543),
endometrioid (OR = 0.22 [0.39–1.78], p = 0.639), and
mucinous tumours (OR = 0.24 [0.42–1.68], p = 0.622).
In multivariate analysis, the independent prognostic fac-
tors for better overall survival of patients with stage III and
IV ovarian cancer were optimal cytoreductive surgery (p =
0.0001), age (<65 years) (p = 0.002) and serous carcino-
mas (p = 0.015). Univariate Cox analysis showed that neo-
adjuvant chemotherapy did not influence the overall (HR
= 0.89, CI [0.74–1.08], p = 0.252) and progression-free
survival (HR = 0.86, CI [0.71–1.04], p  = 0.131) for
patients with stage III ovarian cancer. According to the
estimates of the multivariate Cox analysis, age, stage,
tumour morphology, optimal surgery, and the number of
the first-line chemotherapy cycles were similar predictors
of overall (HR = 0.91, CI [0.75–1.11], p = 0.401) and pro-
gression-free survival (HR = 0.90, CI [0.74–1.09], p =
0.299) for the adjuvant and neoadjuvant chemotherapy
groups of patients with stage III ovarian cancer.
The results of univariate and multivariate Cox analyses for
patients with stage IV ovarian cancer were similar to those
in patients with stage III ovarian cancer. Univariate Cox
Progression-free survival for patients with stage III and IV  ovarian cancer in the neoadjuvant chemotherapy and adju- vant chemotherapy groups Figure 2
Progression-free survival for patients with stage III and IV 
ovarian cancer in the neoadjuvant chemotherapy and adju-
vant chemotherapy groups.
Overall survival for patients with stage III and IV ovarian can- cer in the neoadjuvant chemotherapy and adjuvant chemo- therapy groups Figure 1
Overall survival for patients with stage III and IV ovarian can-
cer in the neoadjuvant chemotherapy and adjuvant chemo-
therapy groups.BMC Cancer 2006, 6:153 http://www.biomedcentral.com/1471-2407/6/153
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analysis showed that the application of neoadjuvant
chemotherapy, comparing to adjuvant chemotherapy, did
not influence the overall (HR = 1.10, CI [0.74–1.64], p =
0.614) and progression-free survival (HR = 1.30, CI
[0.87–1.94], p = 0.186). According to the estimates of the
multivariate Cox analysis, age, stage, tumour morphol-
ogy, optimal surgery, and the number of the first-line
chemotherapy cycles were similar predictors of overall
(HR = 1,15, CI [0.76–1.75], p = 0.494) and progression-
free survival (HR = 1.36, CI [0.90–2.08], p = 0.140) for the
adjuvant and neoadjuvant chemotherapy groups of
patients with stage IV ovarian cancer.
Discussion
Surgery influences the survival of patients with advanced
ovarian cancer [23]. Vergote I. et al. showed that the
median survival of patients is increased only after a com-
plete removal of a tumour (tumour mass after cytoreduc-
tive surgery is <1 g) [24]. Optimal cytoreductive surgery is
possible in only to 40–50% of patients with advanced
stage ovarian cancer [3]. Five-year survival after not opti-
mal cytoreductive surgery does not exceed 10% [25].
Instead of standard treatment by cytoreductive surgery
and adjuvant chemotherapy, patients with advanced ovar-
ian cancer are also treated with neoadjuvant chemother-
apy (drug-induced preoperative cytoreduction), which in
the opinion of some investigators can create better condi-
tions for optimal cytoreductive surgery. It is believed that
such treatment with neoadjuvant chemotherapy improves
the survival of patients. Neoadjuvant chemotherapy
makes more conservative surgery feasible and, for patients
with poor performance status, decreases the risk of post-
operative complications. Unfortunately, up to now no
randomized studies evaluating the efficacy of neoadju-
vant chemotherapy in patients with advanced ovarian
cancer have been conducted. Some published studies are
mainly retrospective and numbers of patients treated with
neoadjuvant chemotherapy and analysed in these studies
are small.
The survival of patients treated with neoadjuvant chemo-
therapy following cytoreductive surgery is similar to those
in whom treatment was started with cytoreductive surgery
[13,14,19,20,26,27]. Some studies showed that neoadju-
vant chemotherapy increases the overall or progression-
free survival [8-11]. In contrast to those data, the results of
our study showed that the rate of optimal surgery and sur-
vival of patients with ovarian cancer did not increase after
neoadjuvant chemotherapy. Nevertheless, more advanced
tumours in the group of patients who underwent neoad-
juvant chemotherapy, and similar overall and disease-free
survival results in both treatment groups allow for the
assumption that neoadjuvant chemotherapy might have a
positive impact in patients with advanced ovarian carci-
nomas. Prospective randomized clinical trials are needed
to clarify the validity of neoadjuvant chemotherapy.
Usually, neoadjuvant chemotherapy is administered
expecting that inoperable tumours will decrease in size,
and it will be possible to perform optimal surgery leading
to better survival results. Only a few studies showed signif-
icantly better tumour resection rates after neoadjuvant
chemotherapy comparing to conventional treatment
[8,17]. We established that independently of patients' age,
the possibility to perform optimal surgery after neoadju-
vant chemotherapy did not increase in patients with stage
III and IV ovarian cancer. A similar number of optimal
cytoreductive procedures in both groups shows that neo-
adjuvant chemotherapy administered in the presence of
more extensive ovarian cancer might increase the possibil-
ity to perform optimal surgery. It was assumed that neo-
adjuvant chemotherapy could improve the chance of
optimal surgery and survival for selected patients who
cannot be debulked optimally using primary cytoreduc-
tive surgery [11]. Currently, there are no established crite-
ria that would help to determine which treatment –
neoadjuvant or adjuvant chemotherapy – should be
administered to patients with advanced ovarian cancer.
Future investigations are needed in order to identify
patients who will benefit from neoadjuvant chemother-
apy.
Conclusion
There was no difference in progression-free or overall sur-
vival, although patients receiving neoadjuvant chemo-
therapy had a more extensive disease. The rate of optimal
cytoreductive surgery was not statistically different
between the neoadjuvant and adjuvant chemotherapy
groups; however, neoadjuvant chemotherapy was admin-
istered in cases of more extensive ovarian cancer. Multi-
variate analysis did not prove that neoadjuvant
chemotherapy could be an independent prognostic factor
for survival, and the findings need to be investigated in
future prospective randomised studies.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
A.I. initiated the study, participated in its design and coor-
dination, carried out the study, and drafted the manu-
script. A.S. carried out the study. E.J. participated in the
design and coordination of the study. J.K. performed the
statistical analysis. R.N. participated in the coordination
of the study. E.S. participated in the design of the study
and helped to draft the manuscript. S.K. participated in
the coordination of the study. All authors read and
approved the final manuscript.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2006, 6:153 http://www.biomedcentral.com/1471-2407/6/153
Page 7 of 7
(page number not for citation purposes)
Acknowledgements
The Authors are grateful to the Lithuanian Cancer Registry for supplying 
the data. They also thank the oncologists of Klaipeda hospital and Kaunas 
Oncology hospital for contributing clinical material.
References
1. Jemal A, Thomas A, Murray T, Thun M: Cancer statistics, 2002.  CA
Cancer J Clin 2002, 52:23-47.
2. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ:
Survival effect of maximal cytoreductive surgery for
advanced ovarian carcinoma during the platinum era: a
meta-analysis.  J Clin Oncol 2002, 20:1248-1259.
3. Inciura A, Juozaityte E, Nadisauskiene R, Cigriejiene VM, Kajenas S,
Vaitkiene D, Vaidotiene L, Simavicius A: Surgical treatment of
advanced epithelial ovarian cancer.  Medicina 2004, 40:205-215.
4. Rose PG, Nerenstone S, Brady M, Clarke-Pearson D, Olt G, Rubin
SC, Moore DH: A phase III randomized study of interval sec-
ondary cytoreduction in patients with advanced stage ovar-
ian carcinoma with suboptimal residual disease: a
Gynecologic Oncology Group study [abstract].  Proc Am Soc
Clin Oncol 2002, 21:201a.
5. Chambers JT, Chambers SK, Voynick IM, Schwartz PE: Neoadjuvant
chemotherapy in stage X ovarian carcinoma.  Gynecol Oncol
1990, 37:327-331.
6. Morice P, Brehier-Ollive D, Rey A, Atallah D, Lhomme C, Pautier P,
Pomel C, Camatte S, Duvillard P, Castaigne D: Results of interval
debulking surgery in advanced stage ovarian cancer: an
exposed-non-exposed study.  Ann Oncol 2003, 14:74-77.
7. Mazzeo F, Berliere M, Kerger J, Squifflet J, Duck L, D'Hondt V,
Humblet Y, Donnez J, Machiels JP: Neoadjuvant chemotherapy
followed by surgery and adjuvant chemotherapy in patients
with primarily unresectable, advanced-stage ovarian cancer.
Gynecol Oncol 2003, 90:163-169.
8. Kuhn W, Rutke S, Spathe K, Schmalfeldt B, Florack G, von Hun-
delshausen B, Pachyn D, Ulm K, Graeff H: Neoadjuvant chemo-
therapy followed by tumor debulking prolongs survival for
patients with poor prognosis in International Federation of
Gynecology and Obstetrics stage IIIC ovarian carcinoma.
Cancer 2001, 92:2585-2591.
9. Onnis A, Marchetti M, Padovan P, Castellan L: Neoadjuvant chem-
oterapy in advanced ovarian cancer.  Eur J Gynaecol Oncol 1996,
17:393-396.
10. Shimizu Y, Hasumi K: Treatment of stage III and IV ovarian can-
cer: is neoadjuvant chemotherapy effective?  Nippon Sanka
Fujinka Gakkai Zasshi 1993, 45:1007-1014.
11. Vergote IB, De Wever I, Decloedt J, Tjalma W, Van Gramberen M,
van Dam P: Neoadjuvant chemotherapy versus primary
debulking surgery in advanced ovarian cancer.  Sem Oncol
2000, 27:31-36.
12. Surwit E, Childers J, Atlas I: Neoadjuvant chemotherapy for
advanced ovarian cancer.  Int J Gynecol Cancer 1996, 6:356-361.
13. Schwartz PE, Rutherford TJ, Chambers JT, Kohorn EI, Thiel RP: Neo-
adjuvant chemoterapy for advanced ovarian cancer: long
term survival.  Gynecol Oncol 1999, 72:93-99.
14. Jacob JH, Gershenson DM, Morris M, Copeland LJ, Burke TW, Whar-
ton JT: Neoadjuvant chemoterapy and interval debulking for
advanced epithelial ovarian cancer.  Gynecol Oncol 1991,
42:146-150.
15. Lim JT, Green JA: Neoadjuvant carboplatin and ifosfamide
chemoterapy for inoperable FIGO stage III and IV ovarian
carcinoma.  Clin Oncol 1993, 5:198-202.
16. Lawton FG, Redman CW, Luesley DM, Chan KK, Blackledge G: Neo-
adjuvant (cytoreductive) chemotherapy combined with
intervention debulking surgery in advanced, unresected epi-
thelial ovarian cancer.  Obstetr Gynecol 1989, 73:61-65.
17. Ansquer Y, Leblanc E, Clough K, Morice P, Dauplat J, Mathevet P,
Lhomme C, Scherer C, Tigaud JD, Benchaib M, Fourme E, Castaigne
D, Querleu D, Dargent D: Neoadjuvant chemotherapy for
unresectable ovarian carcinoma: a French multicenter
study.  Cancer 2001, 91:2329-2334.
18. Recchia F, De Filipps S, Rosselli M, Saggio G, Carta G, Rea S: Primary
chemotherapy in stage IV ovarian cancer. A prospective
phase II study.  Eur J Gynaecol Oncol 2001, 22:287-291.
19. Loizzi V, Cormio G, resta L, Rossi CA, Di Gilio AR, Cuccovillo A, Sel-
vaggi L: Neoadjuvant chemotherapy in advanced ovarian can-
cer: a case-control study.  Int J Gynecol Cancer 2005, 15:217-223.
20. Kayikcioglu F, Kose MF, Boran N, Caliskan E, Tulunay G: Neoadju-
vant chemotherapy of primary surgery in advanced epithe-
lial ovarian carcinoma.  Int J Gynecol Cancer 2001, 11:466-470.
21. Morice P, Dubernard G, Rey A, Atallah D, Pautier P, Pomel C,
Lhomme C, Duvillard P, Castaigne D: Results of interval debulk-
ing surgery compared with primary debulking surgery in
advanced stage ovarian cancer.  J Am Coll Surg 2003,
197:955-963.
22. Ivanov S, Ivanov S, Khadzhiolov N: Prognostic factors and better
survival rate after the treatment of advanced ovarian cancer
with neoadjuvant chemotherapy.  Akush Ginekol 2004, 43:17-9.
23. Hoskins WJ: Surgical staging and cytoreductive surgery of epi-
thelial ovarian cancer.  Cancer 1993, 71:1534-1540.
24. Vergote IB, De Wever I, Tjalma W, Van Gramberen M, Decloedt J,
van Dam P: Neoadjuvant chemoterapy or primary debulking
surgery in advanced ovarian carcinoma: a retrospective anal-
ysis of 258 patients.  Gynecol Oncol 1998, 71:431-436.
25. Huober J, Meyer A, Wagner U, Wallwiener D: The role of neoad-
juvant chemoterapy and interval laparatomy in advanced
ovarian cancer.  J Cancer Res Clin Oncol 2002, 128:153-160.
26. Neijt JP, ten Bokkel Huinink WW, van der Burg ME, van Oosterom
AT, Willemse PH, Heintz AP, van Lent M, Trimbos JB, Bouma J, Ver-
morken JB: Randomized trial comparing two combination
chemotherapy regimens (CHAP-5 v CP) in advanced ovar-
ian carcinoma.  J Clin Oncol 1987, 5:1157-1168.
27. Hegazy M, Hegazi R, Elshafei M, Elshamy M, Eltatoongy M, Halim A:
Neoadjuvant chemotherapy versus primary surgery in
advanced ovarian carcinoma.  World J Surg Oncol 2005, 3:57.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/6/153/pre
pub